09/03/2024 | Press release | Distributed by Public on 09/03/2024 14:38
Item 8.01 Other Events
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
Telomir Pharmaceuticals, Inc. (the "Company") has appointed Dr. Itzchak Angel as Chief Scientific Advisor pursuant to a consulting agreement, effective August 28, 2024, with Dr. Angel's firm, with Angel Pharmaceutical Consulting & Technologies Ltd.
Dr. Angel brings over 30 years of experience in the pharmaceutical industry to the Company, including his role as Head of Pharmacology at Synthelabo (now Sanofi-Aventis). He played a key role in the development of several successful drugs, including Xatral (Alfuzosin), Ambien (Zolpidem), and Mizollen (Mizolastine).
In his new role, Dr. Angel will guide the Company in its pursuit of dual Investigational New Drug (IND) and Investigational New Animal Drug (INAD) submissions for Telomir-1, a novel small molecule designed to lengthen DNA's telomere caps. Telomir-1 has potential applications in conditions such as progeria, a rare genetic disorder that causes accelerated aging. The Company is exploring various regulatory pathways, including the potential for orphan drug status for human indications, to expedite the approval process.
For veterinary applications, the Company is considering the potential of seeking Minor Use and Minor Species (MUMS) designation, which could provide regulatory incentives for treating less common conditions in major species, such as dogs. The Company is currently conducting ongoing scientific research and studies to further explore Telomir-1's potential in both human and veterinary uses, with Dr. Angel leading these efforts to navigate the regulatory landscape effectively.
Cautionary Note Regarding Forward Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "plans," "anticipate," "believe," "estimate," "continue" and similar words. Such statements are only predictions and actual events or results may differ materially from those anticipated in these forward-looking statements. You should not place undue reliance on any forward-looking statements. In this report, such forward-looking statements relate to the anticipated benefits of Dr. Angel's appointment as Chief Scientific Advisor to the Company and other forward-looking matters related to the Company's plans as described herein. Readers are cautioned that actual future results related to Dr. Angel's efforts or Telomir-1 generally may deviate materially and adversely from the forward-looking statements contained herein. The Company does not assume any obligation to update forward-looking statements as circumstances change, except as required by securities laws.